aTyr Pharma, which is developing a new class of protein therapeutics for rare muscular dystrophies, raised $75 million by offering 5.4 million shares at $14, the midpoint of the range of $13 to $15. aTyr Pharma plans to list on the NASDAQ under the symbol LIFE. aTyr Pharma initially filed confidentially on 12/22/2014. J.P. Morgan and Citi acted as lead managers on the deal.
